Full Text View
Tabular View
No Study Results Posted
Related Studies
Identifying Genetic Determinants of Eczema Herpeticum and Other Viral Infections in Individuals With Atopic Dermatitis (Genetics)
This study is currently recruiting participants.
Study NCT00515047   Information provided by National Institute of Allergy and Infectious Diseases (NIAID)
First Received: August 10, 2007   Last Updated: May 26, 2009   History of Changes

August 10, 2007
May 26, 2009
May 2006
 
Identification of variants/haplotypes in EH-associated genes and characterization of frequencies of variants in priority candidate genes for EH [ Time Frame: Throughout Study ] [ Designated as safety issue: No ]
The identification of variants/haplotypes in candidate genes associated with EH and the characterization of frequencies of variants in priority candidate genes for EH according to African American and Caucasian race. [ Time Frame: 4 years ]
Complete list of historical versions of study NCT00515047 on ClinicalTrials.gov Archive Site
Identification and prioritization of novel genes induced in response to viral infection (HSV/Vaccinia and MCV) in AD participants and relevant control groups [ Time Frame: Throughout Study ] [ Designated as safety issue: No ]
The identification and prioritization of novel genes induced in response to viral infection (HSV/Vaccinia and MCV) in AD subjects and relevant control groups. [ Time Frame: 4 years ]
 
Identifying Genetic Determinants of Eczema Herpeticum and Other Viral Infections in Individuals With Atopic Dermatitis
Genetics of Atopic Dermatitis - Eczema Herpeticum

People with atopic dermatitis (AD), or eczema, are susceptible to skin infections and inflammations. Some individuals with AD develop a condition known as eczema herpeticum (EH) following exposure to the herpes simplex virus (HSV). The purpose of this study is to identify the genetic determinants that lead people with AD to develop EH and similar conditions caused by other viruses.

AD is a chronic inflammatory skin disorder characterized by recurrent viral skin infections. However, people with AD do not all develop the same infections. For example, some people with AD who receive the smallpox vaccine develop a life-threatening condition known as eczema vaccinatum (EV). This study focuses on individuals with AD who also have a history of eczema herpeticum (ADEH+), a condition similar to EV. It is unlikely that the differences in the development of skin infections are due to differences in viral exposure, and instead due to differences in each individual's response to viruses. The purpose of this study is to determine the genetic pathways which are responsible for the development of viral skin infections in people with AD. To explore this objective, exposure to three viruses will be used to stimulate gene expression: HSV-1, vaccinia, and molluscum contagiosum.

Participants in this study will also be enrolled in the ADVN Biomarker Registry Study. There will be only one clinical visit for this study at which blood and/or skin samples may be collected. The samples will then be exposed to the viruses and high-throughput genotyping and gene expression profiling experiments will be used to define genetic markers in individuals susceptible to viral infections.

 
Observational
Other, Cross-Sectional
Atopic Dermatitis
 
  • People with AD will provide samples that will be exposed to HSV-1 to stimulate gene expression
  • People with AD will provide samples that will be exposed vaccinia to stimulate gene expression
  • People with AD will provide samples that will be exposed molluscum contagiosum to stimulate gene expression

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Recruiting
1000
January 2010
 

Inclusion Criteria:

  • Enrollment in ADVN Biomarker Registry Study
  • Non-Hispanic and only African American or only Caucasian race
  • Parent or guardian willing to provide informed consent, if necessary

Exclusion Criteria:

  • History of any systemic illness, excluding AD
  • Participation of a first degree relative already enrolled in the genotyping study unless the subject in question fulfills the diagnostic criteria for ADEH+. More information on this criterion can be found in the protocol.
Both
8 Months to 80 Years
Yes
Contact: Judy Lairsmith (303) 270-2413 lairsmithj@NJHealth.org
United States
 
NCT00515047
Associate Director, Clinical Research Program, DAIT/NIAID
DAIT ADVN GENE 04, HHSN266200400033
National Institute of Allergy and Infectious Diseases (NIAID)
 
Principal Investigator: Lisa Beck, MD University of Rochester
Principal Investigator: Kathleen Barnes, PhD Johns Hopkins Allergy and Asthma Center
National Institute of Allergy and Infectious Diseases (NIAID)
May 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP